These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 22067307)

  • 1. The treatment of neuroendocrine tumors with long-acting somatostatin analogs: a single center experience with lanreotide autogel.
    Bianchi A; De Marinis L; Fusco A; Lugli F; Tartaglione L; Milardi D; Mormando M; Lassandro AP; Paragliola R; Rota CA; Della Casa S; Corsello SM; Brizi MG; Pontecorvi A
    J Endocrinol Invest; 2011 Oct; 34(9):692-7. PubMed ID: 22067307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors.
    Ricci S; Antonuzzo A; Galli L; Orlandini C; Ferdeghini M; Boni G; Roncella M; Mosca F; Conte PF
    Am J Clin Oncol; 2000 Aug; 23(4):412-5. PubMed ID: 10955874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo-Controlled, Double-Blind and 32-Week Open-Label Study.
    Fisher GA; Wolin EM; Liyanage N; Pitman Lowenthal S; Mirakhur B; Pommier RF; Shaheen M; Vinik A;
    Oncologist; 2018 Jan; 23(1):16-24. PubMed ID: 29038234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical utility of lanreotide Autogel
    Paragliola RM; Prete A; Papi G; Torino F; Corsello A; Pontecorvi A; Corsello SM
    Drug Des Devel Ther; 2016; 10():3459-3470. PubMed ID: 27822010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of lanreotide in Korean patients with metastatic, well-differentiated gastroenteropancreatic-neuroendocrine tumors: a retrospective analysis.
    Kang J; Yoo C; Hwang HS; Hong SM; Kim KP; Kim SY; Hong YS; Kim TW; Ryoo BY
    Invest New Drugs; 2019 Aug; 37(4):763-770. PubMed ID: 30536151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Neuroendocrine Tumors in Routine Clinical Practice in Germany and Austria.
    Rinke A; Maintz C; Müller L; Weber MM; Lahner H; Pavel M; Saeger W; Houchard A; Ungewiss H; Petersenn S
    Exp Clin Endocrinol Diabetes; 2021 Jul; 129(7):500-509. PubMed ID: 34293802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly.
    Caron P; Beckers A; Cullen DR; Goth MI; Gutt B; Laurberg P; Pico AM; Valimaki M; Zgliczynski W
    J Clin Endocrinol Metab; 2002 Jan; 87(1):99-104. PubMed ID: 11788630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms.
    Wymenga AN; Eriksson B; Salmela PI; Jacobsen MB; Van Cutsem EJ; Fiasse RH; Välimäki MJ; Renstrup J; de Vries EG; Oberg KE
    J Clin Oncol; 1999 Apr; 17(4):1111. PubMed ID: 10561168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Four-year follow-up of acromegalic patients treated with the new long-acting formulation of Lanreotide (Lanreotide Autogel).
    Gutt B; Bidlingmaier M; Kretschmar K; Dieterle C; Steffin B; Schopohl J
    Exp Clin Endocrinol Diabetes; 2005 Mar; 113(3):139-44. PubMed ID: 15789272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL.
    Vinik AI; Wolin EM; Liyanage N; Gomez-Panzani E; Fisher GA;
    Endocr Pract; 2016 Sep; 22(9):1068-80. PubMed ID: 27214300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
    Pavel ME; Phan AT; Wolin EM; Mirakhur B; Liyanage N; Pitman Lowenthal S; Fisher GA; Vinik AI;
    Oncologist; 2019 Apr; 24(4):463-474. PubMed ID: 30355775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
    Caplin ME; Pavel M; Ćwikła JB; Phan AT; Raderer M; Sedláčková E; Cadiot G; Wolin EM; Capdevila J; Wall L; Rindi G; Langley A; Martinez S; Blumberg J; Ruszniewski P;
    N Engl J Med; 2014 Jul; 371(3):224-33. PubMed ID: 25014687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide.
    Ricci S; Antonuzzo A; Galli L; Ferdeghini M; Bodei L; Orlandini C; Conte PF
    Ann Oncol; 2000 Sep; 11(9):1127-30. PubMed ID: 11061606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined Lanreotide Autogel and Temozolomide Treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET Study.
    Pavel M; Lahner H; Hörsch D; Rinke A; Denecke T; Koch A; Regnault B; Helbig D; Hoffmanns P; Raderer M
    Oncologist; 2024 May; 29(5):e643-e654. PubMed ID: 38206830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of lanreotide autogel in Japanese patients with unresectable or metastatic well-differentiated neuroendocrine tumors.
    Ito T; Honma Y; Hijioka S; Kudo A; Fukutomi A; Nozaki A; Kimura Y; Motoi F; Isayama H; Komoto I; Hisamatsu S; Nakajima A; Shimatsu A
    Invest New Drugs; 2017 Aug; 35(4):499-508. PubMed ID: 28470558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An update on the safety of lanreotide autogel for the treatment of patients with neuroendocrine tumors.
    Sood A; Munir M; Syed O; Mehta V; Kaur R; Kumar A; Sridhar A; Sood A; Gupta R
    Expert Opin Drug Saf; 2024 Aug; 23(8):949-957. PubMed ID: 38847075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAÏVE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY.
    Fisher GA; Wolin EM; Liyanage N; Lowenthal SP; Mirakhur B; Pommier RF; Shaheen M; Vinik AI;
    Endocr Pract; 2018 Mar; 24(3):243-255. PubMed ID: 29547049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study.
    Martín-Richard M; Massutí B; Pineda E; Alonso V; Marmol M; Castellano D; Fonseca E; Galán A; Llanos M; Sala MA; Pericay C; Rivera F; Sastre J; Segura A; Quindós M; Maisonobe P;
    BMC Cancer; 2013 Sep; 13():427. PubMed ID: 24053191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism.
    Shimatsu A; Teramoto A; Hizuka N; Kitai K; Ramis J; Chihara K
    Endocr J; 2013; 60(5):651-63. PubMed ID: 23337477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study.
    Bajetta E; Procopio G; Catena L; Martinetti A; De Dosso S; Ricci S; Lecchi AS; Boscani PF; Iacobelli S; Carteni G; De Braud F; Loli P; Tartaglia A; Bajetta R; Ferrari L
    Cancer; 2006 Nov; 107(10):2474-81. PubMed ID: 17054107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.